NEW YORK, NY--(Marketwire -03/19/12)- Biotechnology stocks continue to be some of the strongest performers in the markets as favorable legislation out of Washington boosts the sector's reach. The iShares NASDAQ Biotechnology Index (IBB) is currently up more than 16 percent year to date, reflecting an uptick in investor sentiment. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on MannKind Corporation (NASDAQ: MNKD - News) and Celsion Corporation (NASDAQ: CLSN - News). Access to the full company reports can be found at:

http://www.paragonreport.com/MNKD

http://www.paragonreport.com/CLSN

Earlier this month the Biotechnology Industry Organization applauded the Faster Access to Specialized Treatments (FAST) Act. According to BIO the legislation will modernize the Accelerated Approval pathway to expedite the development of modern, targeted, and personalized therapies for patients suffering from serious and life-threatening diseases.

BIO President and CEO Jim Greenwood says the FAST act will speed access to innovative new therapies and cures to patients living with debilitating and life-threatening diseases such as Parkinson's, Alzheimer's, diabetes and numerous rare diseases for which there is currently no treatment or cure.

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at http://www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.

MannKind Corporation focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States, Europe, and Asia. MannKind did not generate any revenues in the fourth quarter of 2011 -- same as in the year-ago quarter. The net loss applicable to common stockholders for the fourth quarter of 2011 was $36.4 million, or $0.30 per share based on 122.4 million weighted average shares outstanding.

Celsion Corporation develops and commercializes targeted chemotherapeutic oncology drugs based on its proprietary heat-activated liposomal technology. For the year ended December 31, 2011, Celsion reported a net loss of $23.2 million, or $1.11 per share, compared to a net loss of $18.8 million, or $1.52 per share, in 2010.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer

Follow this link:
Biotech Stocks on the Upswing as Favorable Legislation Boosts Investor Optimism